Decreased Risk of Developing Cancer in Subjects Carrying
            <i>SLC52A3</i>
            Rs13042395 Polymorphism: Proof from a Meta-Analysis

Li, Jun; Wang, Shilong; Li, Man; Xu, Hui; Li, Dandan; Yin, Can; Zhao, Jin; Li, Feng

doi:10.2217/bmm-2016-0158

Cited by 2 publications

(3 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For 51 SNPs identified by meta‐analysis, 38 SNPs had statistically significant association with EC or ESCC susceptibility . Meta‐analysis results showed that there were 27 SNPs associated with increased EC or ESCC risk, whereas 11 SNPs decreased the risk of EC or ESCC risk.…”

Section: Resultsmentioning

confidence: 94%

Cumulative evidence for association between genetic polymorphisms and esophageal cancer susceptibility: A review with evidence from meta‐analysis and genome‐wide association studies

Tian

Liu

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

An increasing number of publications had reported the association between single‐nucleotide polymorphisms (SNPs) and esophageal cancer (EC) risk in the past decades. Results from these publications were controversial. We used PubMed, Medline, and Web of Science to identify meta‐analysis articles published before 30 July 2018, that summarize a comprehensive investigation for cumulative evidence of genetic polymorphisms of EC and its subtype risk. Two methods, Venice criteria and false‐positive report probability (FPRP) tests, were used to assess cumulative evidence of significant associations. At last, 107 meta‐analyses were considered to be in conformity with the inclusion criteria, yielding 51 variants associated with EC or esophageal squamous cell carcinoma (ESCC). Thirty‐eight variants were considered to be nominally significant associated with risk of EC or ESCC, whereas the rest showed non‐association. In additional, five variants on five genes were rated as strong cumulative epidemiological evidence for a nominally significant association with EC and ESCC risk, including CYP1A1 rs1048943, EGF rs444903, HOTAIR rs920778, MMP2 rs243865, and PLCE1 rs2274223, 10 variants were rated as moderate, and 18 variants were rated as weak. Additionally, 17 SNPs were verified noteworthy in six genomewide association studies (GWAS) using FPRP methods. Collectively, this review offered a comprehensively referenced information with cumulative evidence of associations between genetic polymorphisms and EC and ESCC risk.

show abstract

Section: Resultsmentioning

confidence: 94%

Cumulative evidence for association between genetic polymorphisms and esophageal cancer susceptibility: A review with evidence from meta‐analysis and genome‐wide association studies

Tian

Liu

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…SLC52A3 was essential for absorption of riboflavin, which was a critical component of the mitochondrial electron transport chain, and loss functional mutation of SLC52A3 may lead to Brown‐Vialetto‐Van Laere syndrome, a rare neurological disorder characterized by bulbar palsies and sensorineural deafness 12 . As for the cancer risk, riboflavin supplement was thought to reduce various types of cancer risks, 13 and several cancer risk research found that SLC52A3 SNPs was associated with oesophageal cancer risk, 14‐16 probably activated by NF‐κB p65/Rel‐B 17 . Previous studies also found that SLC52A3 rs13042395 C > T change could promote glioma cancer cell progression and migration in vivo and in vitro 18 .…”

Section: Discussionmentioning

confidence: 99%

“…We firstly detected protein ( Figure S1B). 12 As for the cancer risk, riboflavin supplement was thought to reduce various types of cancer risks, 13 and several cancer risk research found that SLC52A3 SNPs was associated with oesophageal cancer risk, [14][15][16] probably activated by NF-κB p65/Rel-B. 17 Previous studies also found that SLC52A3 rs13042395 C > T change could promote glioma cancer cell progression and migration in vivo and in vitro.…”

Section: Slc52a3 Regulates Malignant Phenotype Of Gastric Cancer Cementioning

confidence: 99%

Functional variation of SLC52A3 rs13042395 predicts survival of Chinese gastric cancer patients

Cheng

Zhao

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Over 679 000 patients suffered from gastric carcinoma (GCa) with an estimated nearly 500 000 GCa-related deaths in 2015, making it the second most deadly cancer in China. 1 Despite the advance achieved in surgery, chemotherapy, radiotherapy and targeted therapies in the past few decades, the median overall survival (OS) of advanced GCa remained 10-12 months. 2 Hence, it was critical to select poor survival GCa patients for earlier intervention which was promising to prolong the survival time of them. Recently, several biomarkers were identified for the prognosis of GCa which was potentially able to select high-risk patients,

show abstract

Decreased Risk of Developing Cancer in Subjects Carrying SLC52A3 Rs13042395 Polymorphism: Proof from a Meta-Analysis

Abstract: SLC52A3 rs13042395 C>T polymorphism might be a potential biomarker for cancer susceptibility.

Cited by 2 publications

References 45 publications

Cumulative evidence for association between genetic polymorphisms and esophageal cancer susceptibility: A review with evidence from meta‐analysis and genome‐wide association studies

Cumulative evidence for association between genetic polymorphisms and esophageal cancer susceptibility: A review with evidence from meta‐analysis and genome‐wide association studies

Functional variation of SLC52A3 rs13042395 predicts survival of Chinese gastric cancer patients

Contact Info

Product

Resources

About